These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1725608)

  • 21. [Hemorrhagic congenital diseases: What can be the future of plasma-derived products against recombinants?].
    Schved JF
    Transfus Clin Biol; 2015 Aug; 22(3):85-9. PubMed ID: 25933512
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The quality of blood products in Mississippi takes another leap forward.
    Jett PL
    J Miss State Med Assoc; 1999 Nov; 40(11):390-1. PubMed ID: 10568090
    [No Abstract]   [Full Text] [Related]  

  • 23. Approaches to plasma fractionation for improved recovery and the development of potentially useful clinical factors.
    Johnson AJ; Mathews RW; Fulton AJ
    Clin Haematol; 1984 Feb; 13(1):3-15. PubMed ID: 6426834
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The donor of blood and its components.
    Högman CF
    Schweiz Med Wochenschr Suppl; 1991; 43():111-4. PubMed ID: 1843033
    [No Abstract]   [Full Text] [Related]  

  • 25. Update on pathogen reduction technology for therapeutic plasma: an overview.
    Solheim BG; Seghatchian J
    Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathogen reduction of blood components.
    Solheim BG
    Transfus Apher Sci; 2008 Aug; 39(1):75-82. PubMed ID: 18602343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Traceability of drugs derived from blood: regulation and pharmaco-economic implications after 24 months of application in Paris CHU].
    Lesne-Hulin A; Bourget P; Silvie M; Barath V; Singlas E
    Pathol Biol (Paris); 1997 Nov; 45(9):741-50. PubMed ID: 9538473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chemistry and function of human plasma proteins.
    Schwick HG; Haupt H
    Angew Chem Int Ed Engl; 1980 Feb; 19(2):87-99. PubMed ID: 6769370
    [No Abstract]   [Full Text] [Related]  

  • 29. Transfusion therapy in congenital coagulopathies.
    Lusher JM
    Hematol Oncol Clin North Am; 1994 Dec; 8(6):1167-80. PubMed ID: 7860443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New high-technology products for the treatment of haemophilia.
    Pipe SW; Saint-Remy JM; Walsh CE
    Haemophilia; 2004 Oct; 10 Suppl 4():55-63. PubMed ID: 15479373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Which is the foreseeable future role of ethanol fractionation for the production of the main fractions albumin and immunoglobulins, as well as for the preparation of concentrates of trace proteins like coagulation factors? What is the evidence for a superior performance and practicability of other manufacturing procedures?
    Vox Sang; 1981 Jan; 40(1):48-63. PubMed ID: 6784343
    [No Abstract]   [Full Text] [Related]  

  • 32. Are we giving enough coagulation factors during major trauma resuscitation?
    Ho AM; Karmakar MK; Dion PW
    Am J Surg; 2005 Sep; 190(3):479-84. PubMed ID: 16105540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Engineered antibodies take center stage.
    Huston JS; George AJ
    Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Modern methods for the manufacture of therapeutic coagulation factors].
    Fuhge P; Gratz P; Geiger H
    Behring Inst Mitt; 1986 Feb; (79):165-76. PubMed ID: 3087341
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Threatened future of plasma products. Who is responsible?].
    Berntorp E; Nilsson IM; Wollheim FA
    Lakartidningen; 1996 Oct; 93(40):3443-4. PubMed ID: 8926816
    [No Abstract]   [Full Text] [Related]  

  • 37. Steps towards an effective treatment strategy in congenital factor VII deficiency.
    Mariani G; Lapecorella M; Dolce A
    Semin Hematol; 2006 Jan; 43(1 Suppl 1):S42-7. PubMed ID: 16427385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The potentials of current transfusion hematology for component therapy with thrombocytes, granulocytes, plasma and plasma factors in obstetrics and gynecology].
    Nikolov A; Kovachev I; Gŭrcheva L; Dimitrov A
    Akush Ginekol (Sofiia); 1998; 37(4):50-2. PubMed ID: 10360056
    [No Abstract]   [Full Text] [Related]  

  • 39. [Everyone and nobody has the responsibility for the future of plasma products].
    Sjölin S
    Lakartidningen; 1996 Nov; 93(46):4137, 4139. PubMed ID: 8984263
    [No Abstract]   [Full Text] [Related]  

  • 40. Quo vadis haemapheresis. Current developments in haemapheresis.
    Borberg H
    Transfus Apher Sci; 2006 Feb; 34(1):51-73. PubMed ID: 16412691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.